Skip to main content
. 2016 Mar 14;7(16):22834–22845. doi: 10.18632/oncotarget.8071

Figure 3. Immunophenotypes of PBMCs and plasma concentration of cytokines in HCC patients with different leukocyte mtDNA content.

Figure 3

A-C. Flow cytometry analyses for percentage of CD4+ in PBMCs, Treg cells in CD4+ T cells and NK-cells in PBMCs from HCC patients with high and low mtDNA content (both n = 20). D-F. ELISA analyses for the plasma concentrations of TGF-β1, TNF-α and IFN-γ from HCC patients with high and low mtDNA content (both n = 20).